We mentioned the Risperdal litigation in the Johnson & Johnson section of this issue and I am now going to expand the discussion of the litigation. Beasley Allen lawyers continue to pursue Risperdal claims on behalf of individuals who have been injured as a result of taking Risperdal, a brand name drug manufactured by Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson. Risperdal went on the market in 1993 after receiving approval from the FDA for the treatment of schizophrenia. In 2003, the drug was approved for short-term treatment of acute manic/mixed episodes associated with Bipolar I Disorder in adults.
Until 2006, the drug was not approved for any indication to treat minors. In 1997, the FDA denied a request by Janssen for a pediatric indication for the drug. Despite this denial, Janssen marketed the drug for the treatment of depression, anxiety, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), conduct disorder, sleep disorders, anger management and mood enhancement/stabilization.
In 2006, Janssen obtained approval to market the drug for autistic irritability for children and adolescents between the ages of 5 to 16. In 2007, Janssen obtained approval to market the drug for treatment of schizophrenia in adolescents between the ages of 13 to 17 and short-term treatment of manic or mixed episodes of Bipolar I Disorder in children and adolescents between the ages of 10 to 17. Use of Risperdal can cause gynecomastia (enlarged breasts in males), galactorrhea (milky nipple discharge), weight gain, hyperglycemia, diabetes and inhibited reproductive function.
In January 2015, the trial judge in Philadelphia ruled that the statute of limitations under Pennsylvania law began to run as of June 30, 2009, for individuals that used Risperdal before October 2006. The judge entered a case management order that applied the January 2015 ruling to many Risperdal cases pending in Philadelphia. This ruling has been appealed and is now pending before a Pennsylvania appellate court. The January 2015 ruling may not bar claims for injuries that arose after June 30, 2009, provided the lawsuit was filed within two years of the discovery of the injury.
On Dec. 11, 2015, a Philadelphia jury awarded $500,000 to a Plaintiff who had taken Risperdal as a minor. When the Plaintiff started taking Risperdal, the warning label indicated that gynecomastia was a rare side effect and only occurred in less than one in 1,000 patients. In 2006, the Risperdal label was updated to indicate that there was a 2.3 percent rate of gynecomastia in minors taking Risperdal. The Philadelphia jury rejected Janssen’s argument that the Plaintiff’s gynecomastia resulted from puberty instead of Risperdal.
To date, there have been four Risperdal trials in Philadelphia. In three of the trials, the juries have awarded damages against Janssen. In the other trial, the jury found that the warnings provided by Janssen were not adequate, but did not find that Risperdal usage caused that Plaintiff’s injuries.
On Jan. 11, 2016, the United States Supreme Court refused to review a verdict against Janssen in a case filed by the State of South Carolina. That state’s Supreme Court affirmed a substantial verdict against Janssen in favor of the State of South Carolina arising out of deceptive marketing of Risperdal.
If you or a loved one has suffered an injury as a result of taking Risperdal, or you need more information on the subject, contact James Lampkin, a lawyer in our firm’s Mass Torts Section, at 800-898-2034 or by email at James.Lampkin@BeasleyAllen.com.
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.